Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Neurocrine Biosciences, Inc.    NBIX

NEUROCRINE BIOSCIENCES, INC.

(NBIX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/24/2020 11/25/2020 11/27/2020 11/30/2020 12/01/2020 Date
95.81(c) 95.12(c) 95.56(c) 94.94(c) 94.83(c) Last
1 178 223 858 255 364 510 1 845 569 959 869 Volume
+2.34% -0.72% +0.46% -0.65% -0.12% Change
More quotes
Financials (USD)
Sales 2020 1 073 M - -
Net income 2020 125 M - -
Net cash position 2020 655 M - -
P/E ratio 2020 71,8x
Yield 2020 -
Sales 2021 1 298 M - -
Net income 2021 375 M - -
Net cash position 2021 1 213 M - -
P/E ratio 2021 25,4x
Yield 2021 -
Capitalization 8 870 M 8 870 M -
EV / Sales 2020 7,66x
EV / Sales 2021 5,90x
Nbr of Employees 825
Free-Float 97,2%
More Financials
Company
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA... 
Sector
Biotechnology & Medical Research
Calendar
12/01 | 07:50pmPräsentation
More about the company
Notations Surperformance© of Neurocrine Biosciences, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about NEUROCRINE BIOSCIENCES, INC.
11/24NEUROCRINE BIOSCIENCES INC : Other Events (form 8-K)
AQ
11/20NEUROCRINE BIOSCIENCES : Announces Repurchase of Convertible Notes
AQ
11/20NEUROCRINE BIOSCIENCES : to Present at Upcoming Healthcare Conferences
AQ
11/19NEUROCRINE BIOSCIENCES : to Present at Upcoming Healthcare Conferences
PR
11/19NEUROCRINE BIOSCIENCES INC : Other Events (form 8-K)
AQ
11/19NEUROCRINE BIOSCIENCES : Announces Repurchase of Convertible Notes
PR
11/09NEUROCRINE : 3Q Earnings Snapshot
AQ
11/09NEUROCRINE BIOSCIENCES : Management's Discussion and Analysis of Financial Condi..
AQ
11/09NEUROCRINE BIOSCIENCES INC : Results of Operations and Financial Condition (form..
AQ
11/09NEUROCRINE BIOSCIENCES : Reports Third Quarter 2020 Financial Results
PR
11/09NEUROCRINE BIOSCIENCES : to Present at Upcoming Healthcare Conferences
PR
11/04NEUROCRINE BIOSCIENCES, INC. : quaterly earnings release
10/09NEUROCRINE BIOSCIENCES : and Xenon Pharmaceuticals Provide Regulatory Update on ..
AQ
10/08NEUROCRINE BIOSCIENCES : and Xenon Pharmaceuticals Provide Regulatory Update on ..
AQ
10/06NEUROCRINE BIOSCIENCES : Announces Conference Call and Webcast of Third Quarter ..
PR
More news
News in other languages on NEUROCRINE BIOSCIENCES, INC.
11/04NEUROCRINE BIOSCIENCES, INC. : Veröffentlichung des Quartalsergebnisses
11/04NEUROCRINE BIOSCIENCES, INC. : publication des résultats trimestriels
10/27Idorsia schreibt nach neun Monaten weniger Verlust
10/27Idorsia réduit ses pertes sur neuf mois
07/29NEUROCRINE BIOSCIENCES, INC. : Veröffentlichung des Halbjahresergebnisses
More news
Chart NEUROCRINE BIOSCIENCES, INC.
Duration : Period :
Neurocrine Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROCRINE BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 125,75 $
Last Close Price 94,94 $
Spread / Highest target 69,6%
Spread / Average Target 32,5%
Spread / Lowest Target -5,20%
EPS Revisions
Managers
NameTitle
Kevin Charles Gorman Chief Executive Officer & Director
William H. Rastetter Chairman
Matthew C. Abernethy Chief Financial Officer
Dimitri E. Grigoriadis Chief Research Officer
Bill Wilson Vice President-Information Technology & Operations
Sector and Competitors
1st jan.Capitalization (M$)
NEUROCRINE BIOSCIENCES, INC.-11.10%8 870
GILEAD SCIENCES, INC.-6.63%76 052
VERTEX PHARMACEUTICALS4.02%59 224
REGENERON PHARMACEUTICALS37.43%54 464
WUXI APPTEC CO., LTD.56.53%38 135
BIONTECH SE266.71%29 915